Therapeutic Potential of Herbal Medicine against Non-alcoholic Fatty
Liver Disease

doi:10.2174/1389450124666230113150116
摘要

非酒精性脂肪性肝病（NAFLD）是一种常见的代谢紊乱，与肥胖、糖尿病、血脂异常和心血管疾病有关。“多次命中”模型是该疾病复杂发病机制的广泛接受的解释。尽管我们对NAFLD潜在过程的了解有所提高，但不存在常规的药物治疗。目前唯一批准的选择是改变生活方式，例如改变饮食和身体活动。使用药用植物治疗NAFLD最近引起了人们的兴趣。因此，我们根据临床和临床前研究回顾了有关这些药物的当前知识。此外，NAFLD与结直肠癌（CRC）之间的关联，结直肠癌是最常见和致命的恶性肿瘤之一，最近已成为一个新的研究领域。我们概述了NAFLD患者共同的失调途径和草药预防CRC的潜在治疗效果。
关键词: NAFLD，代谢紊乱，药用植物，结直肠癌，生活方式，血脂异常。
« Previous Next »
[1]
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol  2018; 15(1): 11-20.
 [http://dx.doi.org/10.1038/nrgastro.2017.109] [PMID: 28930295]

[2]
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology  2010; 51(5): 1820-32.
 [http://dx.doi.org/10.1002/hep.23594] [PMID: 20432259]

[3]
Streba LAM, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question. World J Gastroenterol  2015; 21(14): 4103-10.
 [http://dx.doi.org/10.3748/wjg.v21.i14.4103] [PMID: 25892859]

[4]
Cariou B. The metabolic triad of NAFLD, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes Obes Metab  2022; 24(s20): 15-27.
 [http://dx.doi.org/10.1111/dom.14651]

[5]
Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol  2015; 7(3): 575-82.
 [http://dx.doi.org/10.4254/wjh.v7.i3.575] [PMID: 25848481]

[6]
Liu Q, Zhu L, Cheng C, Hu YY, Feng Q. Natural active compounds from plant food and Chinese herbal medicine for nonalcoholic fatty liver disease. Curr Pharm Des  2017; 23(34): 5136-62.
 [PMID: 28925892]

[7]
Panyod S, Sheen LY. Beneficial effects of Chinese herbs in the treatment of fatty liver diseases. J Tradit Complement Med  2020; 10(3): 260-7.
 [http://dx.doi.org/10.1016/j.jtcme.2020.02.008] [PMID: 32670821]

[8]
Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol  2010; 5(1): 145-71.
 [http://dx.doi.org/10.1146/annurev-pathol-121808-102132] [PMID: 20078219]

[9]
Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol  2015; 62(1): S47-64.
 [http://dx.doi.org/10.1016/j.jhep.2014.12.012] [PMID: 25920090]

[10]
Pafili K, Roden M. Nonalcoholic Fatty Liver Disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab  2021; 50: 101122.
 [http://dx.doi.org/10.1016/j.molmet.2020.101122] [PMID: 33220492]

[11]
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism  2016; 65(8): 1038-48.
 [http://dx.doi.org/10.1016/j.metabol.2015.12.012] [PMID: 26823198]

[12]
Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol  2014; 20(7): 1746-55.
 [http://dx.doi.org/10.3748/wjg.v20.i7.1746] [PMID: 24587652]

[13]
Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol  2010; 53(2): 372-84.
 [http://dx.doi.org/10.1016/j.jhep.2010.04.008] [PMID: 20494470]

[14]
Hotamisligil GS. Inflammation and metabolic disorders. Nature  2006; 444(7121): 860-7.
 [http://dx.doi.org/10.1038/nature05485] [PMID: 17167474]

[15]
Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A. Hepatocyte apoptosis, expression of death receptors, and activation of NF-κ B in the liver of nonalcoholic and alcoholic steatohepatitis patients. Official J Am College Gastroenterol  2004; 99(9): 1708-17.

[16]
Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med  2005; 11(2): 183-90.
 [http://dx.doi.org/10.1038/nm1166] [PMID: 15685173]

[17]
Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol  2010; 10(11): 753-66.
 [http://dx.doi.org/10.1038/nri2858] [PMID: 20972472]

[18]
Luedde T, Schwabe RF. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol  2011; 8(2): 108-18.
 [http://dx.doi.org/10.1038/nrgastro.2010.213] [PMID: 21293511]

[19]
Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol  2012; 57(3): 642-54.
 [http://dx.doi.org/10.1016/j.jhep.2012.03.035] [PMID: 22634126]

[20]
Zafari N, Velayati M, Fahim M, et al. Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospective. Life Sci  2022; 305: 120760.
 [http://dx.doi.org/10.1016/j.lfs.2022.120760] [PMID: 35787997]

[21]
Klein I, Cornejo JC, Polakos NK, et al. Kupffer cell heterogeneity: functional properties of bone marrow–derived and sessile hepatic macrophages. Blood  2007; 110(12): 4077-85.
 [http://dx.doi.org/10.1182/blood-2007-02-073841] [PMID: 17690256]

[22]
Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut  2006; 55(3): 415-24.
 [http://dx.doi.org/10.1136/gut.2005.071118] [PMID: 16174657]

[23]
Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A. The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol  2002; 22(24): 8571-9.
 [http://dx.doi.org/10.1128/MCB.22.24.8571-8579.2002] [PMID: 12446776]

[24]
De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature  2001; 414(6861): 308-13.
 [http://dx.doi.org/10.1038/35104560] [PMID: 11713530]

[25]
Schwabe RF, Brenner DA. Mechanisms of Liver Injury. I. TNF-α-induced liver injury: Role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol  2006; 290(4): G583-9.
 [http://dx.doi.org/10.1152/ajpgi.00422.2005] [PMID: 16537970]

[26]
Yan H, Gao YQ, Zhang Y, Wang H, Liu GS, Lei JY. Chlorogenic acid alleviates autophagy and insulin resistance by suppressing JNK pathway in a rat model of nonalcoholic fatty liver disease. J Biosci  2018; 43(2): 287-94.
 [http://dx.doi.org/10.1007/s12038-018-9746-5] [PMID: 29872017]

[27]
Susutlertpanya W, Werawatganon D, Siriviriyakul P, Klaikeaw N. Genistein attenuates nonalcoholic steatohepatitis and increases hepatic PPARγ in a rat model. Evid Based Complement Alter Med  2015; 2015: 509057.

[28]
Vailas M, Sotiropoulou M, Katsaros I, et al. Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. Saudi J Gastroenterol  2021; 27(6): 319-30.
 [http://dx.doi.org/10.4103/sjg.sjg_249_21] [PMID: 34810376]

[29]
Salvoza N, Giraudi PJ, Tiribelli C, Rosso N. Natural compounds for counteracting Nonalcoholic Fatty Liver Disease (NAFLD): advantages and limitations of the suggested candidates. Int J Mol Sci  2022; 23(5): 2764.
 [http://dx.doi.org/10.3390/ijms23052764] [PMID: 35269912]

[30]
Mirmiran P, Amirhamidi Z, Ejtahed H-S, Bahadoran Z, Azizi F. Relationship between diet and non-alcoholic fatty liver disease: a review article. Iran J Public Health  2017; 46(8): 1007-17.
 [PMID: 28894701]

[31]
Praveenraj P, Gomes RM, Kumar S, et al. Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese south Indian patients undergoing bariatric surgery. Obes Surg  2015; 25(11): 2078-87.
 [http://dx.doi.org/10.1007/s11695-015-1655-1] [PMID: 25835982]

[32]
Cho EJ, Yu SJ, Jung GC, et al. Body weight gain rather than body weight variability is associated with increased risk of nonalcoholic fatty liver disease. Sci Rep  2021; 11(1): 14428.
 [http://dx.doi.org/10.1038/s41598-021-93883-5] [PMID: 34257374]

[33]
Heredia NI, Gaba R, Liu Y, et al. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep  2022; 12(1): 5695.
 [http://dx.doi.org/10.1038/s41598-022-09583-1] [PMID: 35383229]

[34]
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology  2018; 67(1): 328-57.
 [http://dx.doi.org/10.1002/hep.29367] [PMID: 28714183]

[35]
Glass LM, Dickson RC, Anderson JC, et al. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci  2015; 60(4): 1024-30.
 [http://dx.doi.org/10.1007/s10620-014-3380-3] [PMID: 25354830]

[36]
Scragg J, Avery L, Cassidy S, et al. Feasibility of a very low calorie diet to achieve a sustainable 10% weight loss in patients with nonalcoholic fatty liver disease. Clin Transl Gastroenterol  2020; 11(9): e00231.
 [http://dx.doi.org/10.14309/ctg.0000000000000231] [PMID: 33094956]

[37]
Hohenester S, Christiansen S, Nagel J, et al. Lifestyle intervention for morbid obesity: Effects on liver steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol  2018; 315(3): G329-38.
 [http://dx.doi.org/10.1152/ajpgi.00044.2018] [PMID: 29878845]

[38]
Haas SL, Löfgren P, Stål P, Hoffstedt J. Glucagon and liver fat are downregulated in response to very low-calorie diet in patients with obesity and type-2 diabetes. Exp Clin Endocrinol Diabetes  2022; 130(1): 55-60.
 [http://dx.doi.org/10.1055/a-1220-6160] [PMID: 32767285]

[39]
Diabetes EAftSo. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts  2016; 9(2): 65-90.
 [http://dx.doi.org/10.1159/000443344] [PMID: 27055256]

[40]
Katan MB. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med  2009; 360(9): 923-5.
 [http://dx.doi.org/10.1056/NEJMe0810291] [PMID: 19246365]

[41]
Salehi-sahlabadi A, Sadat S, Beigrezaei S, et al. Dietary patterns and risk of non-alcoholic fatty liver disease. BMC Gastroenterol  2021; 21(1): 41.
 [http://dx.doi.org/10.1186/s12876-021-01612-z] [PMID: 33509112]

[42]
Rakhra V, Galappaththy SL, Bulchandani S, Cabandugama PK. Obesity and the Western diet: How we got here. Missouri Medicine  2020; 117(6): 536.

[43]
Moradi F, Moosavian SP, Djafari F, Teimori A, Imani ZF, Naeini AA. The association between major dietary patterns with the risk of non-alcoholic fatty liver disease, oxidative stress and metabolic parameters: A case–control study. J Diabetes Metab Disord  2022; 21(1): 657-67.
 [http://dx.doi.org/10.1007/s40200-022-01028-w] [PMID: 35673496]

[44]
Giraldi L, Miele L, Aleksovska K, et al. Mediterranean diet and the prevention of non-alcoholic fatty liver disease: results from a case-control study. Eur Rev Med Pharmacol Sci  2020; 24(13): 7391-8.
 [PMID: 32706078]

[45]
Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr  1995; 61(6): 1402S-6S.
 [http://dx.doi.org/10.1093/ajcn/61.6.1402S] [PMID: 7754995]

[46]
Koushki M, Amiri-Dashatan N, Ahmadi N, Abbaszadeh HA, Rezaei-Tavirani M. Resveratrol: A miraculous natural compound for diseases treatment. Food Sci Nutr  2018; 6(8): 2473-90.
 [http://dx.doi.org/10.1002/fsn3.855] [PMID: 30510749]

[47]
Xiao ML, Lin JS, Li YH, et al. Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower presence of non-alcoholic fatty liver disease in middle-aged and elderly adults. Public Health Nutr  2020; 23(4): 674-82.
 [http://dx.doi.org/10.1017/S1368980019002568] [PMID: 31566148]

[48]
Heart N, Lung, Institute B. Your guide to lowering your blood pressure with DASH. Smashbooks.  2006.

[49]
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association. Hepatology  2012; 55(6): 2005-23.
 [http://dx.doi.org/10.1002/hep.25762] [PMID: 22488764]

[50]
Babu AF, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: A systematic review and meta-analysis. Nutrients  2021; 13(9): 3135.
 [http://dx.doi.org/10.3390/nu13093135] [PMID: 34579012]

[51]
Kim SA, Shin S. Fruit and vegetable consumption and non-alcoholic fatty liver disease among Korean adults: A prospective cohort study. J Epidemiol Community Health  2020; 74(12): jech-2020-214568.
 [http://dx.doi.org/10.1136/jech-2020-214568] [PMID: 32796047]

[52]
Cao Y, Wang C, Liu J, Liu Z, Ling W, Chen Y. Greater serum carotenoid levels associated with lower prevalence of nonalcoholic fatty liver disease in Chinese adults. Sci Rep  2015; 5(1): 12951.
 [http://dx.doi.org/10.1038/srep12951] [PMID: 26256414]

[53]
Gostin AI, Waisundara VY. Edible flowers as functional food: A review on artichoke (Cynara cardunculus L.). Trends Food Sci Technol  2019; 86: 381-91.
 [http://dx.doi.org/10.1016/j.tifs.2019.02.015]

[54]
Stumpf B, Künne M, Ma L, et al. Optimization of the extraction procedure for the determination of phenolic acids and flavonoids in the leaves of globe artichoke (Cynara cardunculus var. scolymus L.). J Pharm Biomed Anal  2020; 177: 112879.
 [http://dx.doi.org/10.1016/j.jpba.2019.112879] [PMID: 31542418]

[55]
Zayed A, Farag MA. Valorization, extraction optimization and technology advancements of artichoke biowastes: Food and non- food applications. Lebensm Wiss Technol  2020; 132: 109883.
 [http://dx.doi.org/10.1016/j.lwt.2020.109883]

[56]
Shallan MA, Ali MA, Meshrf WA, Marrez DA. In vitro antimicrobial, antioxidant and anticancer activities of globe artichoke (Cynara cardunculus var. scolymus L.) bracts and receptacles ethanolic extract. Biocatal Agric Biotechnol  2020; 29: 101774.
 [http://dx.doi.org/10.1016/j.bcab.2020.101774]

[57]
Keramati M, Musazadeh V, Ghadimi K. Antioxidant and anti-inflammatory effects of artichoke or Cynara scolymus l. as promising potential therapeutic in anemia. J Nutri Food Secur  2022; 7(1): 129-35.
 [http://dx.doi.org/10.18502/jnfs.v7i1.8544]

[58]
Salem MB, Affes H, Ksouda K, et al. Pharmacological studies of artichoke leaf extract and their health benefits. Plant Foods Hum Nutr  2015; 70(4): 441-53.
 [http://dx.doi.org/10.1007/s11130-015-0503-8] [PMID: 26310198]

[59]
Tang X, Wei R, Deng A, Lei T. Protective effects of ethanolic extracts from artichoke, an edible herbal medicine, against acute alcohol-induced liver injury in mice. Nutrients  2017; 9(9): 1000.
 [http://dx.doi.org/10.3390/nu9091000] [PMID: 28891983]

[60]
Heidarian E, Rafieian-Kopaei M. Protective effect of artichoke (Cynara scolymus) leaf extract against lead toxicity in rat. Pharm Biol  2013; 51(9): 1104-9.
 [http://dx.doi.org/10.3109/13880209.2013.777931] [PMID: 23745593]

[61]
Liao GC, Jhuang JH, Yao HT. Artichoke leaf extract supplementation lowers hepatic oxidative stress and inflammation and increases multidrug resistance-associated protein 2 in mice fed a high-fat and high-cholesterol diet. Food Funct  2021; 12(16): 7239-49.
 [http://dx.doi.org/10.1039/D1FO00861G] [PMID: 34165128]

[62]
Ahmadi A, Heidarian E, Ghatreh-Samani K. Modulatory effects of artichoke (Cynara scolymus L.) leaf extract against oxidative stress and hepatic TNF-α gene expression in acute diazinon-induced liver injury in rats. J Basic Clin Physiol Pharmacol  2019; 30(5): 20180180.
 [http://dx.doi.org/10.1515/jbcpp-2018-0180] [PMID: 31469651]

[63]
Ahmed SF, Abd Al Haleem EN, El-Tantawy WH. Evaluation of the anti-atherogenic potential of Egyptian artichoke leaf extract in hypercholesterolemic rats. Arch Physiol Biochem  2022; 128(1): 163-74.
 [http://dx.doi.org/10.1080/13813455.2019.1669662] [PMID: 31566004]

[64]
Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci  2008; 115(5): 141-50.
 [http://dx.doi.org/10.1042/CS20070402] [PMID: 18662168]

[65]
Panahi Y, Kianpour P, Mohtashami R, et al. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial. Phytother Res  2018; 32(7): 1382-7.
 [http://dx.doi.org/10.1002/ptr.6073] [PMID: 29520889]

[66]
Rangboo V, Noroozi M, Zavoshy R, Rezadoost SA, Mohammadpoorasl A. The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis. Int J Hepatol  2016; 2016 Article ID 4030476.
 [http://dx.doi.org/10.1155/2016/4030476]

[67]
Yazdani Biouki R, Khajahhosseini S, Rad M. The potential of using medicinal herbs in haloculture, a case study of the caper plant (Capparis spinosa L.).  XXX International Horticultural Congress IHC2018: International Symposium on Medicinal and Aromatic Plants, Culinary Herbs, 2018; pp. 1287.

[68]
Tlili N, Nasri N, Saadaoui E, Khaldi A, Triki S. Carotenoid and tocopherol composition of leaves, buds, and flowers of Capparis spinosa grown wild in Tunisia. J Agric Food Chem  2009; 57(12): 5381-5.
 [http://dx.doi.org/10.1021/jf900457p] [PMID: 19473002]

[69]
Rezzan A, Ozan EE, Huseyin S, Oktay Y, Nimet B. Phenolic components, antioxidant activity, and mineral analysis of Capparis spinosa L. Afr J Biotechnol  2013; 12(47): 6643-9.
 [http://dx.doi.org/10.5897/AJB2013.13241]

[70]
Zia-Ul-Haq M, Ćavar S, Qayum M, Imran I, Feo V. Compositional studies: Antioxidant and antidiabetic activities of Capparis decidua (Forsk.) Edgew. Int J Mol Sci  2011; 12(12): 8846-61.
 [http://dx.doi.org/10.3390/ijms12128846] [PMID: 22272107]

[71]
Ramezani Z, Aghel N, Keyghobadi H. Rutin from different parts of Capparis spinosa growing wild in Khuzestan/Iran. Pak J Biol Sci  2008; 11(5): 768-72.
 [http://dx.doi.org/10.3923/pjbs.2008.768.772] [PMID: 18819575]

[72]
Lam SK, Han QF, Ng TB. Isolation and characterization of a lectin with potentially exploitable activities from caper ( Capparis spinosa ) seeds. Biosci Rep  2009; 29(5): 293-9.
 [http://dx.doi.org/10.1042/BSR20080110] [PMID: 18847434]

[73]
Triggiani V, Resta F, Guastamacchia E, Sabbà C, Licchelli B, Ghiyasaldin S. Role of antioxidants, essential fatty acids, carnitine, vitamins, phytochemicals and trace elements in the treatment of diabetes mellitus and its chronic complications. Endocrine, Metabol Immune Disorders-Drug Targets  2006; 6(1): 77-93.
 [http://dx.doi.org/10.2174/187153006776056611]

[74]
Khavasi N, Somi M, Khadem E, et al. Effect of daily caper fruit pickle consumption on disease regression in patients with non-alcoholic fatty liver disease: A double-blinded randomized clinical trial. Adv Pharm Bull  2017; 7(4): 645-50.
 [http://dx.doi.org/10.15171/apb.2017.077] [PMID: 29399555]

[75]
Gull T, Anwar F, Sultana B, Alcayde MAC, Nouman W. Capparis species: A potential source of bioactives and high-value components: A review. Ind Crops Prod  2015; 67: 81-96.
 [http://dx.doi.org/10.1016/j.indcrop.2014.12.059]

[76]
Manikandaselvi S, Brindha P, Vadivel V. Pharmacognostic and pharmacological studies on flower buds of Capparis spinosa L. Int J Pharm Qual Assur  2018; 9(3): 246-52.

[77]
Akbari R, Yaghooti H, Jalali MT, Khorsandi LS, Mohammadtaghvaei N. Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating srebp-1c and a pparα-independent pathway in high-fat diet-fed rats. Research square  2021; 15(1): 1-8.
 [http://dx.doi.org/10.21203/rs.3.rs-523948/v1]

[78]
Riaz G, Chopra R. A review on phytochemistry and therapeutic uses of Hibiscus sabdariffa L. Biomed Pharmacother  2018; 102: 575-86.
 [http://dx.doi.org/10.1016/j.biopha.2018.03.023] [PMID: 29597091]

[79]
Bule M, Albelbeisi AH, Nikfar S, Amini M, Abdollahi M. The antidiabetic and antilipidemic effects of Hibiscus sabdariffa: A systematic review and meta-analysis of randomized clinical trials. Food Res Int  2020; 130: 108980.
 [http://dx.doi.org/10.1016/j.foodres.2020.108980] [PMID: 32156406]

[80]
Huong TT, Tuan HM, Van Thong N, et al. Study on the chemical constituents and antioxidant activity of Hibiscus sabdariffa L. calyx. Vietnam J Sci Technol  2020; 58(6A): 174-80.

[81]
Prasomthong J, Limpeanchob N, Daodee S, Chonpathompikunlert P, Tunsophon S. Hibiscus sabdariffa extract improves hepatic steatosis, partially through IRS-1/Akt and Nrf2 signaling pathways in rats fed a high fat diet. Sci Rep  2022; 12(1): 7022.
 [http://dx.doi.org/10.1038/s41598-022-11027-9] [PMID: 35487948]

[82]
Long Q, Chen H, Yang W, Yang L, Zhang L. Delphinidin-3-sambubioside from Hibiscus sabdariffa. L attenuates hyperlipidemia in high fat diet-induced obese rats and oleic acid-induced steatosis in HepG2 cells. Bioengineered  2021; 12(1): 3837-49.
 [http://dx.doi.org/10.1080/21655979.2021.1950259] [PMID: 34281481]

[83]
Stienstra R, Duval C, Müller M, Kersten S. Duval c, Müller M, Kersten S. PPARs, obesity, and inflammation. PPAR Res  2007; 2007: 1-10.
 [http://dx.doi.org/10.1155/2007/95974]

[84]
Marhuenda J, Perez S, Victoria-Montesinos D, et al. A randomized, double-blind, placebo controlled trial to determine the effectiveness a polyphenolic extract (Hibiscus sabdariffa and Lippia citriodora) in the reduction of body fat mass in healthy subjects. Foods  2020; 9(1): 55.
 [http://dx.doi.org/10.3390/foods9010055] [PMID: 31935957]

[85]
Amos A, Khiatah B. Mechanisms of action of nutritionally rich Hibiscus sabdariffa’s therapeutic uses in major common chronic diseases: A literature review. J Am Nutri Assoc  2022; 41(1): 116-24.
 [http://dx.doi.org/10.1080/07315724.2020.1848662] [PMID: 33507846]

[86]
Sun B, Li F, Zhang X, Wang W, Shao J, Zheng Y. Delphinidin-3- O -glucoside, an active compound of Hibiscus sabdariffa calyces, inhibits oxidative stress and inflammation in rabbits with atherosclerosis. Pharm Biol  2022; 60(1): 247-54.
 [http://dx.doi.org/10.1080/13880209.2021.2017469] [PMID: 35130117]

[87]
Chang HC, Peng CH, Yeh DM, Kao ES, Wang CJ. Hibiscus sabdariffa extract inhibits obesity and fat accumulation, and improves liver steatosis in humans. Food Funct  2014; 5(4): 734-9.
 [http://dx.doi.org/10.1039/c3fo60495k] [PMID: 24549255]

[88]
Husain I, Bala K, Khan IA, Khan SI. A review on phytochemicals, pharmacological activities, drug interactions, and associated toxicities of licorice ( Glycyrrhiza sp.). Food Front  2021; 2(4): 449-85.
 [http://dx.doi.org/10.1002/fft2.110]

[89]
Hajiaghamohammadi AA, Ziaee A, Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial. Phytother Res  2012; 26(9): 1381-4.
 [http://dx.doi.org/10.1002/ptr.3728] [PMID: 22308054]

[90]
Chen L, Kan J, Zheng N, et al. A botanical dietary supplement from white peony and licorice attenuates nonalcoholic fatty liver disease by modulating gut microbiota and reducing inflammation. Phytomedicine  2021; 91: 153693.
 [http://dx.doi.org/10.1016/j.phymed.2021.153693] [PMID: 34403877]

[91]
Kikete S, Luo L, Jia B, Wang L, Ondieki G, Bian Y. Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity. Cytotechnology  2018; 70(4): 1097-110.
 [http://dx.doi.org/10.1007/s10616-018-0202-z] [PMID: 29556897]

[92]
Sedighinia F, Safipour Afshar A, Soleimanpour S, Zarif R, Asili J, Ghazvini K. Antibacterial activity of Glycyrrhiza glabra against oral pathogens: An in vitro study. Avicenna J Phytomed  2012; 2(3): 118-24.
 [PMID: 25050240]

[93]
Sun X, Duan X, Wang C, et al. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. Eur J Pharmacol  2017; 806: 75-82.
 [http://dx.doi.org/10.1016/j.ejphar.2017.04.021] [PMID: 28414056]

[94]
Abo El-Magd NF, El-Karef A, El-Shishtawy MM, Eissa LA. Hepatoprotective effects of glycyrrhizin and omega-3 fatty acids on Nuclear Factor-kappa B pathway in thioacetamide-induced fibrosis in rats. Egypt J Basic Appl Sci  2015; 2(2): 65-74.
 [http://dx.doi.org/10.1016/j.ejbas.2014.12.005]

[95]
Rostamizadeh P, Asl SMKH, Far ZG, et al. Effects of licorice root supplementation on liver enzymes, hepatic steatosis, metabolic and oxidative stress parameters in women with nonalcoholic fatty liver disease: A randomized double-blind clinical trial. Phytother Res  2022; 36(10): 3949-56.
 [http://dx.doi.org/10.1002/ptr.7543] [PMID: 35785498]

[96]
Hariri M, Gholami A, Mirhafez SR, Bidkhori M, Sahebkar A. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med  2020; 51: 102447.
 [http://dx.doi.org/10.1016/j.ctim.2020.102447] [PMID: 32507446]

[97]
Chen S, Zhao X, Wan J, et al. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacol Res  2015; 99: 74-81.
 [http://dx.doi.org/10.1016/j.phrs.2015.05.009] [PMID: 26032587]

[98]
Zhang LX, Li CX, Kakar MU, et al. Resveratrol (RV): A pharmacological review and call for further research. Biomed Pharmacother  2021; 143: 112164.
 [http://dx.doi.org/10.1016/j.biopha.2021.112164] [PMID: 34649335]

[99]
Charytoniuk T, Drygalski K, Konstantynowicz-Nowicka K, Berk K, Chabowski A. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. Nutrition  2017; 34: 108-17.
 [http://dx.doi.org/10.1016/j.nut.2016.09.001] [PMID: 28063505]

[100]
Choi YJ, Suh HR, Yoon Y, et al. Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. Arch Pharm Res  2014; 37(9): 1169-76.
 [http://dx.doi.org/10.1007/s12272-014-0347-z] [PMID: 24633463]

[101]
Hosseini H, Teimouri M, Shabani M, et al. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. Int J Biochem Cell Biol  2020; 119: 105667.
 [http://dx.doi.org/10.1016/j.biocel.2019.105667] [PMID: 31838177]

[102]
Aslam M, Ladilov Y. Emerging role of cAMP/AMPK signaling. Cells  2022; 11(2): 308.
 [http://dx.doi.org/10.3390/cells11020308] [PMID: 35053423]

[103]
Gerhart-Hines Z, Dominy JE Jr, Blättler SM, et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol Cell  2011; 44(6): 851-63.
 [http://dx.doi.org/10.1016/j.molcel.2011.12.005] [PMID: 22195961]

[104]
Parsamanesh N, Asghari A, Sardari S, et al. Resveratrol and endothelial function: A literature review. Pharmacol Res  2021; 170: 105725.
 [http://dx.doi.org/10.1016/j.phrs.2021.105725] [PMID: 34119624]

[105]
Pellegrini C, Fornai M, Antonioli L, Blandizzi C, Calderone V. Phytochemicals as novel therapeutic strategies for NLRP3 inflammasome-related neurological, metabolic, and inflammatory diseases. Int J Mol Sci  2019; 20(12): 2876.
 [http://dx.doi.org/10.3390/ijms20122876] [PMID: 31200447]

[106]
Wang ZM, Chen YC, Wang DP. Resveratrol, a natural antioxidant, protects monosodium iodoacetate-induced osteoarthritic pain in rats. Biomed Pharmacother  2016; 83: 763-70.
 [http://dx.doi.org/10.1016/j.biopha.2016.06.050] [PMID: 27484345]

[107]
Pourhanifeh MH, Shafabakhsh R, Reiter RJ, Asemi Z. The effect of resveratrol on neurodegenerative disorders: Possible protective actions against autophagy, apoptosis, inflammation and oxidative stress. Curr Pharm Des  2019; 25(19): 2178-91.
 [http://dx.doi.org/10.2174/1381612825666190717110932] [PMID: 31333112]

[108]
Deng Y, Gong W, Li Q, et al. Resveratrol inhibits high glucose-induced activation of AP-1 and NF-κB via SphK1/S1P2 pathway to attenuate mesangial cells proliferation and inflammation. J Funct Foods  2019; 55: 86-94.
 [http://dx.doi.org/10.1016/j.jff.2019.02.014]

[109]
Liu X, Zhao H, Jin Q, et al. Resveratrol induces apoptosis and inhibits adipogenesis by stimulating the SIRT1-AMPKα-FOXO1 signalling pathway in bovine intramuscular adipocytes. Mol Cell Biochem  2018; 439(1-2): 213-23.
 [http://dx.doi.org/10.1007/s11010-017-3149-z] [PMID: 28819881]

[110]
Truong VL, Jun M, Jeong WS. Role of resveratrol in regulation of cellular defense systems against oxidative stress. Biofactors  2018; 44(1): 36-49.
 [http://dx.doi.org/10.1002/biof.1399] [PMID: 29193412]

[111]
Ahmad I, Hoda M. Molecular mechanisms of action of resveratrol in modulation of diabetic and non-diabetic cardiomyopathy. Pharmacol Res  2020; 161: 105112.
 [http://dx.doi.org/10.1016/j.phrs.2020.105112] [PMID: 32758636]

[112]
Chen S, Zhao X, Ran L, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig Liver Dis  2015; 47(3): 226-32.
 [http://dx.doi.org/10.1016/j.dld.2014.11.015] [PMID: 25577300]

[113]
Ali Sangouni A, Abdollahi S, Mozaffari-Khosravi H. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. BMC Cardiovasc Disord  2022; 22(1): 212.
 [http://dx.doi.org/10.1186/s12872-022-02637-2] [PMID: 35538431]

[114]
Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2019.
 [PMID: 30789808]

[115]
Díaz-Mula HM, Tomás-Barberán FA, García-Villalba R. Pomegranate fruit and juice (cv. Mollar), rich in ellagitannins and anthocyanins, also provide a significant content of a wide range of proanthocyanidins. J Agric Food Chem  2019; 67(33): 9160-7.
 [http://dx.doi.org/10.1021/acs.jafc.8b07155] [PMID: 30768267]

[116]
Butkeviciute A, Viskelis J, Liaudanskas M, Viskelis P, Janulis V. Impact of storage controlled atmosphere on the apple phenolic acids, flavonoids, and anthocyanins and antioxidant activity in vitro. Plants  2022; 11(2): 201.
 [http://dx.doi.org/10.3390/plants11020201] [PMID: 35050089]

[117]
Currie TL, Engler MM, Olsen CH, et al. The effects of berry extracts on oxidative stress in cultured cardiomyocytes and microglial cells: A potential cardioprotective and neuroprotective mechanism. Molecules  2022; 27(9): 2789.
 [http://dx.doi.org/10.3390/molecules27092789] [PMID: 35566133]

[118]
Huang W, Yan Z, Li D, Ma Y, Zhou J, Sui Z. Antioxidant and anti-inflammatory effects of blueberry anthocyanins on high glucose-induced human retinal capillary endothelial cells. Oxidative Medicine and Cellular Longevity  2018; 2018: Article ID 1862462.
 [http://dx.doi.org/10.1155/2018/1862462]

[119]
Vendrame S, Klimis-Zacas D. Potential factors influencing the effects of anthocyanins on blood pressure regulation in humans: a review. Nutrients  2019; 11(6): 1431.
 [http://dx.doi.org/10.3390/nu11061431] [PMID: 31242638]

[120]
Cui HX, Luo Y, Mao YY, et al. Purified anthocyanins from  ZEA MAYS L. cob ameliorates chronic liver injury in mice via modulating of oxidative stress and apoptosis. J Sci Food Agric  2021; 101(11): 4672-80.
 [http://dx.doi.org/10.1002/jsfa.11112] [PMID: 33491773]

[121]
Ma Y, Ding S, Fei Y, Liu G, Jang H, Fang J. Antimicrobial activity of anthocyanins and catechins against foodborne pathogens Escherichia coli and Salmonella. Food Control  2019; 106: 106712.
 [http://dx.doi.org/10.1016/j.foodcont.2019.106712]

[122]
Bayram HM, Majoo FM, Ozturkcan A. Polyphenols in the prevention and treatment of non-alcoholic fatty liver disease: An update of preclinical and clinical studies. Clin Nutr ESPEN  2021; 44: 1-14.
 [http://dx.doi.org/10.1016/j.clnesp.2021.06.026] [PMID: 34330452]

[123]
Parra-Vargas M, Sandoval-Rodriguez A, Rodriguez-Echevarria R, Dominguez-Rosales J, Santos-Garcia A, Armendariz-Borunda J. Delphinidin ameliorates hepatic triglyceride accumulation in human HepG2 cells, but not in diet-induced obese mice. Nutrients  2018; 10(8): 1060.
 [http://dx.doi.org/10.3390/nu10081060] [PMID: 30103390]

[124]
Kim B, Bae M, Park YK, et al. Blackcurrant anthocyanins stimulated cholesterol transport via post-transcriptional induction of LDL receptor in Caco-2 cells. Eur J Nutr  2018; 57(1): 405-15.
 [http://dx.doi.org/10.1007/s00394-017-1506-z] [PMID: 28718016]

[125]
Gomes JVP, Rigolon TCB, Souza MSS, et al. Antiobesity effects of anthocyanins on mitochondrial biogenesis, inflammation, and oxidative stress: A systematic review. Nutrition  2019; 66: 192-202.
 [http://dx.doi.org/10.1016/j.nut.2019.05.005] [PMID: 31310961]

[126]
Aboonabi A, Aboonabi A. Anthocyanins reduce inflammation and improve glucose and lipid metabolism associated with inhibiting nuclear factor-kappaB activation and increasing PPAR-γ gene expression in metabolic syndrome subjects. Free Radic Biol Med  2020; 150: 30-9.
 [http://dx.doi.org/10.1016/j.freeradbiomed.2020.02.004] [PMID: 32061902]

[127]
Zhu X, Lin X, Zhang P, Liu Y, Ling W, Guo H. Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study. Clin Res Hepatol Gastroenterol  2022; 46(4): 101843.
 [http://dx.doi.org/10.1016/j.clinre.2021.101843] [PMID: 34922061]

[128]
Pahlke G, Ahlberg K, Oertel A, et al. Antioxidant effects of elderberry anthocyanins in human colon carcinoma cells: a study on structure–activity relationships. Mol Nutr Food Res  2021; 65(17): 2100229.
 [http://dx.doi.org/10.1002/mnfr.202100229] [PMID: 34212508]

[129]
Ngamlerst C, Udomkasemsab A, Kongkachuichai R, Kwanbunjan K, Chupeerach C, Prangthip P. The potential of antioxidant-rich Maoberry (Antidesma bunius) extract on fat metabolism in liver tissues of rats fed a high-fat diet. BMC Complement Altern Med  2019; 19(1): 294.
 [http://dx.doi.org/10.1186/s12906-019-2716-0] [PMID: 31684925]

[130]
Mohammed HA, Khan RA. Anthocyanins: traditional uses, structural and functional variations, approaches to increase yields and products’ quality, hepatoprotection, liver longevity, and commercial products. Int J Mol Sci  2022; 23(4): 2149.
 [http://dx.doi.org/10.3390/ijms23042149] [PMID: 35216263]

[131]
Zhang PW, Chen FX, Li D, Ling WH, Guo HH. A CONSORT- compliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. Medicine (Baltimore)  2015; 94(20): e758.
 [http://dx.doi.org/10.1097/MD.0000000000000758] [PMID: 25997043]

[132]
LIczbiński P, Bukowska B. Tea and coffee polyphenols and their biological properties based on the latest in vitro investigations. Ind Crops Prod  2022; 175: 114265.
 [http://dx.doi.org/10.1016/j.indcrop.2021.114265] [PMID: 34815622]

[133]
Pinta NM, Montoliu I, Aura AM, Seppänen-Laakso T, Barron D, Moco S. In vitro gut metabolism of [U- 13 C]-quinic acid, the other hydrolysis product of chlorogenic acid. Mol Nutr Food Res  2018; 62(22): 1800396.
 [http://dx.doi.org/10.1002/mnfr.201800396] [PMID: 30113130]

[134]
Olthof MR, Hollman PC, Zock PL, Katan MB. Consumption of high doses of chlorogenic acid, present in coffee, or of black tea increases plasma total homocysteine concentrations in humans. Am J Clin Nutr  2001; 73(3): 532-8.
 [http://dx.doi.org/10.1093/ajcn/73.3.532] [PMID: 11237928]

[135]
Xu J, Gao L, Liang H, Zhang S, Lai P, Chen S. Evidence for the anti-NAFLD effectiveness of chlorogenic acid as a HAT inhibitor using in vivo experiments supported by virtual molecular docking. Phytomedicine Plus  2021; 1(4): 100055.
 [http://dx.doi.org/10.1016/j.phyplu.2021.100055]

[136]
Shi A, Li T, Zheng Y, et al. Chlorogenic acid improves NAFLD by regulating gut microbiota and GLP-1. Front Pharmacol  2021; 12: 693048.
 [http://dx.doi.org/10.3389/fphar.2021.693048] [PMID: 34276380]

[137]
Mansour A, Mohajeri-Tehrani MR, Samadi M, et al. Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled, clinical trial. Nutr J  2021; 20(1): 35.
 [http://dx.doi.org/10.1186/s12937-021-00694-5] [PMID: 33838673]

[138]
Rupasinghe H, Boehm M, Sekhon-Loodu S, Parmar I, Bors B, Jamieson A. Anti-inflammatory activity of haskap cultivars is polyphenols-dependent. Biomolecules  2015; 5(2): 1079-98.
 [http://dx.doi.org/10.3390/biom5021079] [PMID: 26043379]

[139]
Oszmiański J, Wojdyło A, Lachowicz S. Effect of dried powder preparation process on polyphenolic content and antioxidant activity of blue honeysuckle berries (Lonicera caerulea L. var. kamtschatica). Lebensm Wiss Technol  2016; 67: 214-22.
 [http://dx.doi.org/10.1016/j.lwt.2015.11.051]

[140]
Sharma A, Lee HJ. Lonicera caerulea: An updated account of its phytoconstituents and health-promoting activities. Trends Food Sci Technol  2021; 107: 130-49.
 [http://dx.doi.org/10.1016/j.tifs.2020.08.013]

[141]
Wu S, Hu R, Nakano H, et al. Modulation of gut microbiota by Lonicera caerulea L. berry polyphenols in a mouse model of fatty liver induced by high fat diet. Molecules  2018; 23(12): 3213.
 [http://dx.doi.org/10.3390/molecules23123213] [PMID: 30563142]

[142]
Park M, Yoo JH, Lee YS, Lee HJ. Lonicera caerulea extract attenuates non-alcoholic fatty liver disease in free fatty acid-induced HepG2 hepatocytes and in high fat diet-fed mice. Nutrients  2019; 11(3): 494.
 [http://dx.doi.org/10.3390/nu11030494] [PMID: 30813654]

[143]
Takahashi M, Ishiko T, Kamohara H, et al. Curcumin (1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) blocks the chemotaxis of neutrophils by inhibiting signal transduction through IL-8 receptors. Mediators of inflammation  2007; 2007.

[144]
Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Joukar F. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Integr Med Res  2019; 8(1): 57-61.
 [http://dx.doi.org/10.1016/j.imr.2018.07.004] [PMID: 30949432]

[145]
Lee DE, Lee SJ, Kim SJ, Lee HS, Kwon OS. Curcumin ameliorates nonalcoholic fatty liver disease through inhibition of O-GlcNAcylation. Nutrients  2019; 11(11): 2702.
 [http://dx.doi.org/10.3390/nu11112702] [PMID: 31717261]

[146]
Sun Q, Niu Q, Guo Y, et al. Regulation on citrate influx and metabolism through inhibiting SLC13A5 and ACLY: A novel mechanism mediating the therapeutic effects of curcumin on NAFLD. J Agric Food Chem  2021; 69(31): 8714-25.
 [http://dx.doi.org/10.1021/acs.jafc.1c03105] [PMID: 34323067]

[147]
Li W, Jiang L, Lu X, Liu X, Ling M. Curcumin protects radiation-induced liver damage in rats through the NF-κB signaling pathway. BMC Complementary Medicine and Therapies  2021; 21(1): 10.
 [http://dx.doi.org/10.1186/s12906-020-03182-1] [PMID: 33386071]

[148]
Yan C, Zhang Y, Zhang X, Aa J, Wang G, Xie Y. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice. Biomed Pharmacother  2018; 105: 274-81.
 [http://dx.doi.org/10.1016/j.biopha.2018.05.135] [PMID: 29860219]

[149]
Chen WJ, Cai B, Chen HT, et al. Retracted: The role of ADIPOQ methylation in curcumin-administrated experimental nonalcoholic fatty liver disease. J Dig Dis  2016; 17(12): 829-36.
 [http://dx.doi.org/10.1111/1751-2980.12431] [PMID: 27860427]

[150]
Santamarina Aline B, et al. Decaffeinated green tea extract rich in epigallocatechin-3-gallate prevents fatty liver disease by increased activities of mitochondrial respiratory chain complexes in diet-induced obesity mice. J Nutr Biochem  2015; 26(11): 1348-56.

[151]
Hou H, Yang W, Bao S, Cao Y. Epigallocatechin gallate suppresses inflammatory responses by inhibiting toll-like receptor 4 signaling and alleviates insulin resistance in the livers of high-fat-diet rats. J Oleo Sci  2020; 69(5): 479-86.
 [http://dx.doi.org/10.5650/jos.ess19303] [PMID: 32281563]

[152]
Ning K, Lu K, Chen Q, et al. Epigallocatechin gallate protects mice against methionine-choline-deficient-diet-induced nonalcoholic steatohepatitis by improving gut microbiota to attenuate hepatic injury and regulate metabolism. ACS Omega  2020; 5(33): 20800-9.
 [http://dx.doi.org/10.1021/acsomega.0c01689] [PMID: 32875214]

[153]
Yang Z, Zhu M, Zhang Y, et al. Coadministration of epigallocatechin-3-gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats. Phytother Res  2019; 33(4): 1019-26.
 [http://dx.doi.org/10.1002/ptr.6295] [PMID: 30746789]

[154]
Tang GY, Zhao CN, Xu XY, et al. Phytochemical composition and antioxidant capacity of 30 Chinese teas. Antioxidants  2019; 8(6): 180.
 [http://dx.doi.org/10.3390/antiox8060180] [PMID: 31216700]

[155]
Xiao J, Ho CT, Liong EC, et al. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways. Eur J Nutr  2014; 53(1): 187-99.
 [http://dx.doi.org/10.1007/s00394-013-0516-8] [PMID: 23515587]

[156]
Du Y, Paglicawan L, Soomro S, et al. Epigallocatechin-3-gallate dampens non-alcoholic fatty liver by modulating liver function, lipid profile and macrophage polarization. Nutrients  2021; 13(2): 599.
 [http://dx.doi.org/10.3390/nu13020599] [PMID: 33670347]

[157]
Zhang Y, Yin R, Lang J, Fu Y, Yang L, Zhao D. Epigallocatechin-3-gallate ameliorates hepatic damages by relieve FGF21 resistance and promotion of FGF21–AMPK pathway in mice fed a high fat diet. Diabetol Metab Syndr  2022; 14(1): 53.
 [http://dx.doi.org/10.1186/s13098-022-00823-y] [PMID: 35418153]

[158]
Wu D, Liu Z, Wang Y, Zhang Q, Li J, Zhong P, et al. Epigallocatechin-3-gallate alleviates high-fat diet-induced nonalcoholic fatty liver disease via inhibition of apoptosis and promotion of autophagy through the ROS/MAPK signaling pathway. Oxidative Medicine and Cellular Longevity  2021; 2021

[159]
Shang X, Pan H, Wang X, He H, Li M. Leonurus japonicus Houtt.: Ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol  2014; 152(1): 14-32.
 [http://dx.doi.org/10.1016/j.jep.2013.12.052] [PMID: 24412548]

[160]
Lee MR, Park K, Ma J. Leonurus japonicus Houtt attenuates nonalcoholic fatty liver disease in free fatty acid-induced HepG2 cells and mice fed a high-fat diet. Nutrients  2017; 10(1): 20.
 [http://dx.doi.org/10.3390/nu10010020] [PMID: 29295591]

[161]
Kulczyński B, Gramza-Michałowska A. Goji Berry (Lycium barbarum): Composition and health effects–a review. Pol J Food Nutr Sci  2016; 66(2): 67-75.
 [http://dx.doi.org/10.1515/pjfns-2015-0040]

[162]
Zhu L, Peng Z, Zhang X, Yang J, Lai X, Yang G. Determination of polyphenols in Lycium barbarum leaves by high-performance liquid chromatography–tandem mass spectrometry. Anal Lett  2017; 50(5): 761-76.
 [http://dx.doi.org/10.1080/00032719.2016.1202956]

[163]
Potterat O. Goji (Lycium barbarum and L. chinense): Phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity. Planta Med  2010; 76(1): 7-19.
 [http://dx.doi.org/10.1055/s-0029-1186218] [PMID: 19844860]

[164]
Juan C, Montesano D, Mañes J, Juan-García A. Carotenoids present in goji berries Lycium barbarum L. are suitable to protect against mycotoxins effects: An in vitro study of bioavailability. J Funct Foods  2022; 92: 105049.
 [http://dx.doi.org/10.1016/j.jff.2022.105049]

[165]
Xiao J, Wang F, Liong EC, So KF, Tipoe GL. Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model. Int J Biol Macromol  2018; 120(Pt B): 1480-9.
 [http://dx.doi.org/10.1016/j.ijbiomac.2018.09.151] [PMID: 30266645]

[166]
Xiao J, Xing F, Huo J, et al. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model. Sci Rep  2015; 4(1): 5587.
 [http://dx.doi.org/10.1038/srep05587] [PMID: 24998389]

[167]
Jia L, Li W, Li J, et al. Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity. Sci Rep  2016; 6(1): 36209.
 [http://dx.doi.org/10.1038/srep36209] [PMID: 27824080]

[168]
Yang Y, Chen J, Gao Q, Shan X, Wang J, Lv Z. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology  2020; 445: 152599.
 [http://dx.doi.org/10.1016/j.tox.2020.152599] [PMID: 32976958]

[169]
Choi MS, Kim JK, Kim DH, Yoo HH. Effects of gut microbiota on the bioavailability of bioactive compounds from ginkgo leaf extracts. Metabolites  2019; 9(7): 132.
 [http://dx.doi.org/10.3390/metabo9070132] [PMID: 31284440]

[170]
Singh B, Kaur P, Gopichand , Singh RD, Ahuja PS. Biology and chemistry of Ginkgo biloba. Fitoterapia  2008; 79(6): 401-18.
 [http://dx.doi.org/10.1016/j.fitote.2008.05.007] [PMID: 18639617]

[171]
Yan Z, Fan R, Yin S, et al. Protective effects of Ginkgo biloba leaf polysaccharide on nonalcoholic fatty liver disease and its mechanisms. Int J Biol Macromol  2015; 80: 573-80.
 [http://dx.doi.org/10.1016/j.ijbiomac.2015.05.054] [PMID: 26047899]

[172]
Li L, Yang L, Yang F, Zhao X, Xue S, Gong F. Ginkgo biloba extract 50 (GBE50) ameliorates insulin resistance, hepatic steatosis and liver injury in high fat diet-fed mice. J Inflamm Res  2021; 14: 1959-71.
 [http://dx.doi.org/10.2147/JIR.S302934] [PMID: 34040411]

[173]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021; 71(3): 209-49.
 [http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]

[174]
Chen H, Zheng X, Zong X, et al. Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer. Gut  2021; 70(6): 1147-54.
 [http://dx.doi.org/10.1136/gutjnl-2020-321661] [PMID: 33037055]

[175]
O’Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal cancer: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021.
 [PMID: 33524598]

[176]
Wong VWS, Wong GLH, Tsang SWC, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut  2011; 60(6): 829-36.
 [http://dx.doi.org/10.1136/gut.2011.237974] [PMID: 21339204]

[177]
Huang KW, Leu HB, Wang YJ, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis  2013; 15(7): 830-5.
 [http://dx.doi.org/10.1111/codi.12172] [PMID: 23398678]

[178]
Stadlmayr A, Aigner E, Steger B, et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med  2011; 270(1): 41-9.
 [http://dx.doi.org/10.1111/j.1365-2796.2011.02377.x] [PMID: 21414047]

[179]
Zhang X, Wong VWS, Yip TCF, et al. Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory-wide cohort study. Hepatol Commun  2021; 5(7): 1212-23.
 [http://dx.doi.org/10.1002/hep4.1705] [PMID: 34278170]

[180]
Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of colorectal cancer in chronic liver diseases: A systematic review and meta-analysis. Gastrointestinal endoscopy  2017; 86(1): 93-104.
 [http://dx.doi.org/10.1016/j.gie.2016.12.009]

[181]
Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol  2016; 7(2): 211-7.
 [http://dx.doi.org/10.4291/wjgp.v7.i2.211] [PMID: 27190693]

[182]
Song M, Sasazuki S, Camargo MC, et al. Circulating inflammatory markers and colorectal cancer risk: A prospective case-cohort study in Japan. Int J Cancer  2018; 143(11): 2767-76.
 [http://dx.doi.org/10.1002/ijc.31821] [PMID: 30132835]

[183]
Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res  2008; 68(1): 323-8.
 [http://dx.doi.org/10.1158/0008-5472.CAN-07-2924] [PMID: 18172326]

[184]
Tasci I, Dogru T, Ercin CN, Erdem G, Sonmez A. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther  2008; 28(2): 266-7.
 [http://dx.doi.org/10.1111/j.1365-2036.2008.03697.x] [PMID: 18611188]

[185]
Mikolasevic I, Orlic L, Stimac D, Hrstic I, Jakopcic I, Milic S. Non-alcoholic fatty liver disease and colorectal cancer. Postgrad Med J  2017; 93(1097): 153-8.
 [http://dx.doi.org/10.1136/postgradmedj-2016-134383] [PMID: 27852946]

[186]
Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol  2014; 12(10): 661-72.
 [http://dx.doi.org/10.1038/nrmicro3344] [PMID: 25198138]

[187]
Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol  2018; 24(27): 2974-83.
 [http://dx.doi.org/10.3748/wjg.v24.i27.2974] [PMID: 30038464]

[188]
Sokkar HH, Abo Dena AS, Mahana NA, Badr A. Artichoke extracts in cancer therapy: Do the extraction conditions affect the anticancer activity? Future Journal of Pharmaceutical Sciences  2020; 6(1): 78.
 [http://dx.doi.org/10.1186/s43094-020-00088-0]

[189]
Macharia JM, Mwangi RW, Rozmann N, et al. Medicinal plants with anti-colorectal cancer bioactive compounds: Potential game-changers in colorectal cancer management. Biomed Pharmacother  2022; 153: 113383.
 [http://dx.doi.org/10.1016/j.biopha.2022.113383] [PMID: 35820316]

[190]
Fakhri M, Yousefi SS, Moosazadeh M, Azadbakht M, Fakheri H. Relationship between green tea drinking and the risk of colorectal cancer; a systematic review and meta-analysis. Immunopathologia Persa 2022.
 [http://dx.doi.org/10.34172/ipp.2022.29287]

[191]
Villota H, Moreno-Ceballos M, Santa-González GA, et al. Biological impact of phenolic compounds from coffee on colorectal cancer. Pharmaceuticals (Basel)  2021; 14(8): 761.
 [http://dx.doi.org/10.3390/ph14080761] [PMID: 34451858]

[192]
Wang G, Hiramoto K, Ma N, et al. Glycyrrhizin attenuates carcinogenesis by inhibiting the inflammatory response in a murine model of colorectal cancer. Int J Mol Sci  2021; 22(5): 2609.
 [http://dx.doi.org/10.3390/ijms22052609] [PMID: 33807620]

[193]
Qiblawi S, Kausar MA, Shahid SMA, Saeed M, Alazzeh AY. Therapeutic interventions of cardamom in cancer and other human diseases. J Pharm Res Int  2020; 17: 74-84.
 [http://dx.doi.org/10.9734/jpri/2020/v32i2230774]

[194]
Sakata R, Nakamura T, Torimura T, Ueno T, Sata M. Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study. Int J Mol Med  2013; 32(5): 989-94.
 [http://dx.doi.org/10.3892/ijmm.2013.1503] [PMID: 24065295]

[195]
Hosseinabadi S, Rafraf M, Asghari S, Asghari-Jafarabadi M, Vojouhi S. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Complement Ther Med  2020; 49: 102290.
 [http://dx.doi.org/10.1016/j.ctim.2019.102290] [PMID: 32147076]

[196]
Goodarzi R, Jafarirad S, Mohammadtaghvaei N, Dastoorpoor M, Alavinejad P. The effect of pomegranate extract on anthropometric indices, serum lipids, glycemic indicators, and blood pressure in patients with nonalcoholic fatty liver disease: A randomized double-blind clinical trial. Phytother Res  2021; 35(10): 5871-82.
 [http://dx.doi.org/10.1002/ptr.7249] [PMID: 34498307]

[197]
Hormoznejad R, Mohammad Shahi M, Rahim F, Helli B, Alavinejad P, Sharhani A. Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: A double-blind placebo-controlled randomized clinical trial. Int J Food Sci Nutr  2020; 71(8): 991-1000.
 [http://dx.doi.org/10.1080/09637486.2020.1746957] [PMID: 32237922]

[198]
Guo H, Zhong R, Liu Y, et al. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition  2014; 30(2): 198-203.
 [http://dx.doi.org/10.1016/j.nut.2013.07.023] [PMID: 24377455]

[199]
Shidfar F, Bahrololumi SS, Doaei S, Mohammadzadeh A, Gholamalizadeh M, Mohammadimanesh A. The effects of extra virgin olive oil on alanine aminotransferase, aspartate aminotransferase, and ultrasonographic indices of hepatic steatosis in nonalcoholic fatty liver disease patients undergoing low calorie diet. Canadian J Gastroenterol Hepatol  2018; 2018: Article ID 1053710.
 [http://dx.doi.org/10.1155/2018/1053710]

[200]
Sangsefidi ZS, Yarhosseini F, Hosseinzadeh M, et al. The effect of (Cornus mas L.) fruit extract on liver function among patients with nonalcoholic fatty liver: A double-blind randomized clinical trial. Phytother Res  2021; 35(9): 5259-68.
 [http://dx.doi.org/10.1002/ptr.7199] [PMID: 34254372]

[201]
Dorosti M, Jafary Heidarloo A, Bakhshimoghaddam F, Alizadeh M. Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: A randomised controlled clinical trial. Br J Nutr  2020; 123(3): 328-36.
 [http://dx.doi.org/10.1017/S0007114519002769] [PMID: 31685037]

[202]
Whittaker A, Dinu M, Cesari F, et al. A khorasan wheat-based replacement diet improves risk profile of patients with type 2 diabetes mellitus (T2DM): A randomized crossover trial. Eur J Nutr  2017; 56(3): 1191-200.
 [http://dx.doi.org/10.1007/s00394-016-1168-2] [PMID: 26853601]

[203]
Chang HC, Huang CN, Yeh DM, Wang SJ, Peng CH, Wang CJ. Oat prevents obesity and abdominal fat distribution, and improves liver function in humans. Plant Foods Hum Nutr  2013; 68(1): 18-23.
 [http://dx.doi.org/10.1007/s11130-013-0336-2] [PMID: 23371785]

[204]
Khonche A, Huseini HF, Gholamian M, Mohtashami R, Nabati F, Kianbakht S. Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial. J Ethnopharmacol  2019; 234: 106-11.
 [http://dx.doi.org/10.1016/j.jep.2019.01.009] [PMID: 30639231]

[205]
Taghavi SA, Babaei A, Mohammadi A, et al. Comparison of the efficacy of oral fenugreek seeds hydroalcoholic extract versus placebo in nonalcoholic fatty liver disease; a randomized, triple-blind controlled pilot clinical trial. Indian J Pharmacol  2020; 52(2): 86-93.
 [http://dx.doi.org/10.4103/ijp.IJP_17_19] [PMID: 32565595]

[206]
Gheflati A, Adelnia E, Nadjarzadeh A. The clinical effects of purslane (Portulaca oleracea) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. Phytother Res  2019; 33(5): 1501-9.
 [http://dx.doi.org/10.1002/ptr.6342] [PMID: 30895694]

[207]
Darvish Damavandi R, Shidfar F, Najafi M, et al. Effect of Portulaca oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. Phytother Res  2021; 35(6): 3145-56.
 [http://dx.doi.org/10.1002/ptr.6972] [PMID: 33880813]

[208]
Daneshi-Maskooni M, Keshavarz SA, Qorbani M, et al. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: A double-blind randomized placebo-controlled clinical trial. BMC Complement Altern Med  2019; 19(1): 59.
 [http://dx.doi.org/10.1186/s12906-019-2465-0] [PMID: 30871514]

[209]
Zamani N, Shams M, Nimrouzi M, et al. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo- controlled clinical trial. Complement Ther Med  2018; 41: 118-23.
 [http://dx.doi.org/10.1016/j.ctim.2018.09.010] [PMID: 30477827]

[210]
Darand M, Darabi Z, Yari Z, et al. Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med  2019; 44: 204-9.
 [http://dx.doi.org/10.1016/j.ctim.2019.04.014] [PMID: 31126557]

[211]
Hussain M, Tunio AG, Akhtar L, Shaikh GS. Effects of Nigella sativa on various parameters in patients of non-alcoholic fatty liver disease. J Ayub Med Coll Abbottabad  2017; 29(3): 403-7.
 [PMID: 29076670]

[212]
Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res  2014; 34(2): 143-8.
 [http://dx.doi.org/10.1016/j.nutres.2013.11.005] [PMID: 24461315]

[213]
Sangouni AA, Alizadeh M, Jamalzehi A, Parastouei K. Effects of garlic powder supplementation on metabolic syndrome components, insulin resistance, fatty liver index, and appetite in subjects with metabolic syndrome: A randomized clinical trial. Phytother Res  2021; 35(8): 4433-41.
 [http://dx.doi.org/10.1002/ptr.7146] [PMID: 33974725]

[214]
Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: A double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol  2019; 31(5): 613-7.
 [http://dx.doi.org/10.1097/MEG.0000000000001369] [PMID: 30920975]

[215]
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J Cardiovasc Pharmacol  2016; 68(3): 223-9.
 [http://dx.doi.org/10.1097/FJC.0000000000000406] [PMID: 27124606]

[216]
Saadati S, Sadeghi A, Mansour A, et al. Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol  2019; 19(1): 133.
 [http://dx.doi.org/10.1186/s12876-019-1055-4] [PMID: 31345163]

[217]
Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, et al. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complement Ther Med  2020; 49: 102322.
 [http://dx.doi.org/10.1016/j.ctim.2020.102322] [PMID: 32147075]

[218]
Magosso E, Ansari MA, Gopalan Y, et al. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J  2013; 12(1): 166.
 [http://dx.doi.org/10.1186/1475-2891-12-166] [PMID: 24373555]

[219]
Xie X, Meng X, Zhou X, Shu X, Kong H. Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease. Zhongguo Zhongyao Zazhi  2011; 36(21): 3032-5.
 [PMID: 22308697]

[220]
Daniel T, Ben-Shachar M, Drori E, et al. Grape pomace reduces the severity of non-alcoholic hepatic steatosis and the development of steatohepatitis by improving insulin sensitivity and reducing ectopic fat deposition in mice. J Nutr Biochem  2021; 98: 108867.
 [http://dx.doi.org/10.1016/j.jnutbio.2021.108867] [PMID: 34571189]

[221]
Uchiyama H, Komatsu KI, Nakata A, et al. Global liver gene expression analysis on a murine hepatic steatosis model treated with mulberry (Morus alba L.) leaf powder. Anticancer Res  2018; 38(7): 4305-11.
 [http://dx.doi.org/10.21873/anticanres.12729] [PMID: 29970566]

[222]
Zidani S, Benakmoum A, Ammouche A, Benali Y, Bouhadef A, Abbeddou S. Effect of dry tomato peel supplementation on glucose tolerance, insulin resistance, and hepatic markers in mice fed high-saturated-fat/high-cholesterol diets. J Nutr Biochem  2017; 40: 164-71.
 [http://dx.doi.org/10.1016/j.jnutbio.2016.11.001] [PMID: 27907824]

[223]
Lee GH, Peng C, Park SA, et al. Citrus peel extract ameliorates high-fat diet-induced NAFLD via activation of AMPK signaling. Nutrients  2020; 12(3): 673.
 [http://dx.doi.org/10.3390/nu12030673] [PMID: 32121602]

[224]
Lai YS, Chen WC, Ho CT, et al. Garlic essential oil protects against obesity-triggered nonalcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress. J Agric Food Chem  2014; 62(25): 5897-906.
 [http://dx.doi.org/10.1021/jf500803c] [PMID: 24857364]

[225]
Torres L, Cogliati B, Otton R. Green tea prevents NAFLD by modulation of miR-34a and miR-194 expression in a high-fat diet mouse model. Oxidative Medicine and Cellular Longevity  2019; 2019
 [http://dx.doi.org/10.1155/2019/4168380]

[226]
Di Mauro S, Salomone F, Scamporrino A, et al. Coffee restores expression of lncRNAs involved in steatosis and fibrosis in a mouse model of NAFLD. Nutrients  2021; 13(9): 2952.
 [http://dx.doi.org/10.3390/nu13092952] [PMID: 34578828]

[227]
Kim HM, Kim Y, Lee ES, Huh JH, Chung CH. Caffeic acid ameliorates hepatic steatosis and reduces ER stress in high fat diet–induced obese mice by regulating autophagy. Nutrition  2018; 55-56: 63-70.
 [http://dx.doi.org/10.1016/j.nut.2018.03.010] [PMID: 29960159]

[228]
Zhang P, Li J, Li M, Sui Y, Zhou Y, Sun Y. Effects of lycopene on metabolism of glycolipid and inflammation in non-alcoholic fatty liver disease rats. Wei Sheng Yen Chiu  2020; 49(2): 254-71.
 [PMID: 32290942]

[229]
Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr  2012; 107(2): 202-10.
 [http://dx.doi.org/10.1017/S0007114511002753] [PMID: 21733326]

[230]
Liu Q, Pan R, Ding L, et al. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries. Int Immunopharmacol  2017; 49: 132-41.
 [http://dx.doi.org/10.1016/j.intimp.2017.05.026] [PMID: 28577437]

[231]
Sun R, Xu D, Wei Q, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother  2020; 123: 109721.
 [http://dx.doi.org/10.1016/j.biopha.2019.109721] [PMID: 31865143]

[232]
Saleh Al-maamari JN, Rahmadi M, Panggono SM, et al. The effects of quercetin on the expression of SREBP-1c mRNA in high- fat diet-induced NAFLD in mice. J Basic Clin Physiol Pharmacol  2021; 32(4): 637-44.
 [http://dx.doi.org/10.1515/jbcpp-2020-0423] [PMID: 34214346]

[233]
Jian T, Lü H, Ding X, et al. Polyphenol-rich Trapa quadrispinosa pericarp extract ameliorates high-fat diet induced non-alcoholic fatty liver disease by regulating lipid metabolism and insulin resistance in mice. PeerJ  2019; 7: e8165.
 [http://dx.doi.org/10.7717/peerj.8165] [PMID: 31803542]

[234]
Al Zarzour R, Ahmad M, Asmawi M, et al. Phyllanthus niruri standardized extract alleviates the progression of non-alcoholic fatty liver disease and decreases atherosclerotic risk in Sprague–Dawley rats. Nutrients  2017; 9(7): 766.
 [http://dx.doi.org/10.3390/nu9070766] [PMID: 28718838]

[235]
Tan Y, Lao W, Xiao L, Wang Z, Xiao W, Kamal MA, et al. Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome with Chinese herbal extracts in high-fat-diet fed rats. Evidence-Based Complementary and Alternative Medicine  2013; 2013.
 [http://dx.doi.org/10.1155/2013/306738]

[236]
Hong X, Tang H, Wu L, Li L. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. J Pharm Pharmacol  2010; 58(10): 1391-8.
 [http://dx.doi.org/10.1211/jpp.57.10.0013] [PMID: 17034663]

[237]
Chang CJ, Liou SS, Tzeng TF, Liu IM. The ethanol extract of Zingiber zerumbet Smith attenuates non-alcoholic fatty liver disease in hamsters fed on high-fat diet. Food Chem Toxicol  2014; 65: 33-42.
 [http://dx.doi.org/10.1016/j.fct.2013.11.048] [PMID: 24342243]

[238]
Bae UJ, Oh MR, Jung TS, Chae SW, Park BH. Decursin and decursinol angelate-rich Angelica gigas Nakai extract suppresses de novo lipogenesis and alleviates nonalcoholic fatty liver disease and dyslipidemia in mice fed a high fat diet. J Funct Foods  2017; 31: 208-16.
 [http://dx.doi.org/10.1016/j.jff.2017.02.008]
Rights & Permissions Print Cite
Article Metrics
60
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450124666230113150116	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
当代药物靶点

草药对非酒精性脂肪肝的治疗潜力

摘要

Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics

RNA Molecules in the Treatment of Human Diseases

当代药物靶点

草药对非酒精性脂肪肝的治疗潜力

摘要

Call for Papers in Thematic Issues

Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics

RNA Molecules in the Treatment of Human Diseases

Related Journals

Related Books

Related Articles
